Skip to content

Study · In vitro (cells) · 2026

5 results

In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides.

Akhan D, Bicak B, Akman G, Kecel Gunduz S

Cell biochemistry and biophysics7 Jul 2026

PMID42412310 (opens in a new tab)DOI10.1007/s12013-026-02095-z (opens in a new tab)PepBankPUB-42412310
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In MDA-MB-231 cells, Leuphasyl showed among its most pronounced cytotoxic effects.

    In plain wordsIn cells, Leuphasyl showed particularly pronounced toxicity in MDA-MB-231 cancer cells.

    Peptide
    Pentapeptide-18
    Outcome
    IncreaseMDA-MB-231 cytotoxicity
    Study

    humann: not reported in source

    MDA-MB-231 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro MTT assays showed that both peptides exhibited the most pronounced cytotoxic effects in MDA-MB-231 and PC3 cells, supporting their potential selective anticancer activity.
  2. 02LabIn vitro (cells)Activity measurement

    In PC3 cells, Leuphasyl showed among its most pronounced cytotoxic effects.

    In plain wordsIn cells, Leuphasyl showed particularly pronounced toxicity in PC3 cancer cells.

    Peptide
    Pentapeptide-18
    Outcome
    IncreasePC3 cytotoxicity
    Study

    humann: not reported in source

    PC3 cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro MTT assays showed that both peptides exhibited the most pronounced cytotoxic effects in MDA-MB-231 and PC3 cells, supporting their potential selective anticancer activity.

Studies that did not test the peptide alone3

In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pentapeptide-18.

  1. 03Computer modelNot a test of Pentapeptide-18 aloneIn silicoMechanism

    In computational models, Leuphasyl had an EGFR docking score of -10.63 kcal/mol.

    In plain wordsIn computer models, Leuphasyl had an EGFR docking score of -10.63 kcal/mol.

    Peptide
    Pentapeptide-18
    Outcome
    Not applicableEGFR docking score
    Study

    n: not reported in source

    Computational models
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Docking score
    −10.63 kcal/mol
    EGFR-Leuphasyl

    Source sentences

    Summary
    The highest binding was observed for EGFR-Leuphasyl (-10.63 kcal/mol), followed by Vialox-EGFR (-9.24 kcal/mol).

    In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pentapeptide-18.

  2. 04Computer modelNot a test of Pentapeptide-18 aloneIn silicoMechanism

    In computational models, Leuphasyl had a PI3K docking score of -9.15 kcal/mol.

    In plain wordsIn computer models, Leuphasyl had a PI3K docking score of -9.15 kcal/mol.

    Peptide
    Pentapeptide-18
    Outcome
    Not applicablePI3K docking score
    Study

    n: not reported in source

    Computational models
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Docking score
    −9.15 kcal/mol
    Leuphasyl PI3K

    Source sentences

    Summary
    PI3K docking scores were also high, with -9.05 and -9.15 kcal/mol for Vialox and Leuphasyl, respectively.

    In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pentapeptide-18.

  3. 05Computer modelNot a test of Pentapeptide-18 aloneIn silicoMechanism

    In computational models, Leuphasyl relied on hydrophobic interactions and had a binding energy of -46.68 kcal/mol.

    In plain wordsIn computer models, Leuphasyl used hydrophobic interactions and had a binding energy of -46.68 kcal/mol.

    Peptide
    Pentapeptide-18
    Outcome
    Not applicableEGFR binding interactions and energy
    Study

    n: not reported in source

    Computational models
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Binding energy
    −46.68 kcal/mol
    Leuphasyl

    Source sentences

    Summary
    Leuphasyl relies on hydrophobic interactions but has a lower binding energy of -46.68 kcal/mol due to differences in charge distribution and polar interactions.
    1 context sentence
    Summary · context
    MM-GBSA calculations showed that Vialox and Leuphasyl interact differently with the EGFR binding pocket.

    In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pentapeptide-18.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.